• 1
    Glenny AM, O'Meara S, Melville A, Sheldon TA, Wilson C. The treatment and prevention of obesity: a systematic review of the literature. Int J Obes Relat Metab Disord 1997; 21: 71537.
  • 2
    WHO. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization, 2000.
  • 3
    Van Gaal LF. Dietary Treatment of Obesity. In: BrayGA, ed. Handbook of Obesity. New York: Marcel Dekker, 1998: 87590.
  • 4
    Torgerson JS, Lissner L, Lindroos AK, Kruijer H, Sjöström L. VLCD plus dietary and behavioural support versus support alone in the treatment of severe obesity. A randomised two-year clinical trial[published corrigendum appears in Int J Obes Relat Metab Disord 1998; 22: 382]. Int J Obes Relat Metab Disord 1997; 21: 98794.
  • 5
    Ryttig KR, Flaten H, Rössner S. Long-term effects of a very low calorie diet (Nutrilett) in obesity treatment. A prospective, randomized, comparison between VLCD and a hypocaloric diet+behavior modification and their combination. Int J Obes Relat Metab Disord 1997; 21: 5749.
  • 6
    Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 17984.
  • 7
    Wing RR, Epstein LH, Marcus MD, Koeske R. Intermittent low-calorie regimen and booster sessions in the treatment of obesity. Behav Res Ther 1984; 22: 4459.
  • 8
    Kaplan GD, Miller KC, Anderson JW. Comparative weight loss in obese patients restarting a supplemented very-low-calorie diet. Am J Clin Nutr 1992; 56 (1 Suppl.): 290S291S.
  • 9
    Wing RR, Blair E, Marcus M, Epstein LH, Harvey J. Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome? Am J Med 1994; 97: 35462.
  • 10
    Rössner S. Intermittent vs continuous VLCD therapy in obesity treatment. Int J Obes Relat Metab Disord 1998; 22: 1902.
  • 11
    Sjöström CD, Håkangård AC, Lissner L, Sjöström L. Body compartment and subcutaneous adipose tissue distribution – risk factor patterns in obese subjects. Obes Res 1995; 3: 922.
  • 12
    Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990; 51: 110612.
  • 13
    Pietrobelli A, Formica C, Wang Z, Heymsfield SB. Dual-energy X-ray absorptiometry body composition model. review of physical concepts. Am J Physiol 1996; 271: E94151.
  • 14
    Sköldborn H, Arvidsson B, Andersson M. A new whole body monitoring laboratory. Acta Radiol Suppl 1972; 313: 23341.
  • 15
    Hendel HW, Gotfredsen A, Andersen T, Hojgaard L, Hilsted J. Body composition during weight loss in obese patients estimated by dual energy X-ray absorptiometry and by total body potassium. Int J Obes Relat Metab Disord 1996; 20: 11119.
  • 16
    Forbes GB, Lewis AM. Total sodium potassium and chloride in adult man. J Clin Invest 1956; 35: 596600.
  • 17
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499502.
  • 18
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 4129.
  • 19
    Minitab Inc. Minitab Statistical Software. Release 13. 3081. Enterprice Drive, State College, PA 16801-3008, USA.
  • 20
    Pekkarinen T, Mustajoki P. Comparison of behavior therapy with and without very-low-energy diet in the treatment of morbid obesity. A 5-year outcome. Arch Intern Med 1997; 157: 15815.
  • 21
    Torgerson JS, Ågren L, Sjöström L. Effects on body weight of strict or liberal adherence to an initial period of VLCD treatment. A randomised, one-year clinical trial of obese subjects. Int J Obes Relat Metab Disord 1999; 23: 1907.
  • 22
    Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 16772.
  • 23
    James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 211925.
  • 24
    Saris WH. Very-low-calorie diets and sustained weight loss. Obes Res 2001; 9 (Suppl. 4): 295S301S.
  • 25
    Stunkard A, McLaren-Hume M. The results of treatment for obesity. Arch Inter Med 1959; 103: 7985.
  • 26
    Richman R, Burns CM, Steinbeck K, Caterson I. Factors influencing completion and attrition in a weight control programme. In: Ailhaud G, Guy-Grand B, Lafontan M, Ricquier D, eds., Obesity in Europe 91.London: John Libbey, 1992: 16771.
  • 27
    Klein S. Outcome success in obesity. Obes Res 2001; 9 (Suppl. 4): 354S358S.
  • 28
    Sjöström CD, Lissner L, Wedel H, Sjöström L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7: 47784.
  • 29
    Sjöström CD, Peltonen M, Wedel H, Sjöström L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36: 205.
  • 30
    Sjöström L. Surgical intervention as a strategy for treatment of obesity. Endocrine 2000; 13: 21330.
  • 31
    Jebb SA, Goldberg GR. Efficacy of very low-energy diets and meal replacements in the treatment of obesity. J Human Nutr Diet 1998; 11: 21925.
  • 32
    Fogelholm GM, Sievänen HT, Kukkonen-Harjula TK, Pasanen ME. Bone mineral density during reduction, maintenance and regain of body weight in premenopausal, obese women. Osteoporos Int 2001; 12: 199206.